Express Scripts' acquisition reflects strong investing opportunities in the sector.
Medical marijuana is already massively profitable for a handful of states, so it's no surprise pharmaceutical giants want in on the action.
Abbott is about as balanced as it gets in the pharmaceutical sector, and an increase in sales and profit is likely this year.
With only one major patent loss ahead, Merck has potential for relatively modest good performance.
A small California city approves a medical-marijuana nursery -- and will likely see its fortunes improve dramatically.
The pharmaceuticals company has a rough fourth quarter and faces continued uncertainty with 2 manufacturing plants.
Some isolated shares got hammered this week despite good quarterly results. They deserve a look now.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
Servers across US have been surprised -- and delighted -- by 4-figure tips on an American Express card.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.